Literature DB >> 17627168

DNA variation in MSR1, RNASEL and E-cadherin genes and prostate cancer in Poland.

Cezary Cybulski1, Dominika Wokołorczyk, Anna Jakubowska, Bartłomiej Gliniewicz, Andrzej Sikorski, Tomasz Huzarski, Tadeusz Debniak, Steven A Narod, Jan Lubiński.   

Abstract

INTRODUCTION: We investigated whether or not inherited variation in MSR1, RNASEL and E-cadherin contribute to prostate cancer risk in Poland.
MATERIAL AND METHODS: We sequenced the coding region of these three genes in individuals from Poland and identified five common DNA variants (R462Q and D541E in RNASEL, R293X and P275A in MSR1, and 2076C>T (A692A) in E-cadherin). These five variants and the -160C>A promoter change in E-cadherin were genotyped in 737 prostate cancer cases and 511 controls.
RESULTS: The frequencies of genotyped variants in MSR1, RNASEL and E-cadherin genes in cases and controls were similar. We did not see any association for the studied variants when cases were stratified by age of diagnosis, by family history, by prostate-specific antigen level at the time of diagnosis, by Gleason sore or by tumor stage.
CONCLUSIONS: Inherited variation in RNASEL, MSR1 and E-cadherin genes do not seem to contribute to prostate cancer development in Poland.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17627168     DOI: 10.1159/000102913

Source DB:  PubMed          Journal:  Urol Int        ISSN: 0042-1138            Impact factor:   2.089


  14 in total

1.  An update analysis of two polymorphisms in encoding ribonuclease L gene and prostate cancer risk: involving 13,372 cases and 11,953 controls.

Authors:  Yuan-Yuan Mi; Li-Jie Zhu; Sheng Wu; Ning-Han Feng
Journal:  Genes Nutr       Date:  2011-04-17       Impact factor: 5.523

Review 2.  Genetic susceptibility to cancer: the role of polymorphisms in candidate genes.

Authors:  Linda M Dong; John D Potter; Emily White; Cornelia M Ulrich; Lon R Cardon; Ulrike Peters
Journal:  JAMA       Date:  2008-05-28       Impact factor: 56.272

3.  RNASEL Asp541Glu and Arg462Gln polymorphisms in prostate cancer risk: evidences from a meta-analysis.

Authors:  Bingbing Wei; Zhuoqun Xu; Jun Ruan; Ming Zhu; Ke Jin; Deqi Zhou; Zhiqiang Yan; Feng Xuan; Hongyi Zhou; Xing Huang; Jian Zhang; Peng Lu; Jianfeng Shao
Journal:  Mol Biol Rep       Date:  2011-06-09       Impact factor: 2.316

4.  Promoter methylation and polymorphism of E-cadherin gene may confer a risk to prostate cancer: a meta-analysis based on 22 studies.

Authors:  Zheng Chang; Hongbing Zhou; Yi Liu
Journal:  Tumour Biol       Date:  2014-07-24

5.  Genetic variation in RNASEL associated with prostate cancer risk and progression.

Authors:  Mara S Meyer; Kathryn L Penney; Jennifer R Stark; Fredrick R Schumacher; Howard D Sesso; Massimo Loda; Michelangelo Fiorentino; Stephen Finn; Richard J Flavin; Tobias Kurth; Alkes L Price; Edward L Giovannucci; Katja Fall; Meir J Stampfer; Jing Ma; Lorelei A Mucci
Journal:  Carcinogenesis       Date:  2010-06-24       Impact factor: 4.944

6.  RNASEL -1385G/A polymorphism and cancer risk: a meta-analysis based on 21 case-control studies.

Authors:  Li-Feng Zhang; Yuan-Yuan Mi; Chao Qin; Yong Wang; Qiang Cao; Jun-Feng Wei; Yao-Jun Zhou; Ning-Han Feng; Wei Zhang
Journal:  Mol Biol Rep       Date:  2011-01-09       Impact factor: 2.316

7.  Contribution of HPC1 (RNASEL) and HPCX variants to prostate cancer in a founder population.

Authors:  Ilir Agalliu; Suzanne M Leanza; Lorie Smith; Jeffrey M Trent; John D Carpten; Joan E Bailey-Wilson; Robert D Burk
Journal:  Prostate       Date:  2010-11-01       Impact factor: 4.104

8.  Arg462Gln and Asp541Glu polymorphisms in ribonuclease L and prostate cancer risk: a meta-analysis.

Authors:  Yuanyuan Mi; Qianqian Yu; Zhichao Min; Bin Xu; Lifeng Zhang; Wei Zhang; Ninghan Feng; Lixin Hua
Journal:  J Biomed Res       Date:  2010-09

9.  Contribution of the -160C/A polymorphism in the E-cadherin promoter to cancer risk: a meta-analysis of 47 case-control studies.

Authors:  Lin Wang; Guiying Wang; Chenqi Lu; Bo Feng; Jiuhong Kang
Journal:  PLoS One       Date:  2012-07-05       Impact factor: 3.240

10.  Prognostic role of genetic biomarkers in clinical progression of prostate cancer.

Authors:  Maria Jesus Alvarez-Cubero; Luis Javier Martinez-Gonzalez; Maria Saiz; Pedro Carmona-Saez; Juan Carlos Alvarez; Manrique Pascual-Geler; Jose Antonio Lorente; Jose Manuel Cozar
Journal:  Exp Mol Med       Date:  2015-08-07       Impact factor: 8.718

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.